EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

EEDGAR/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice. EDGAR is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. EDGAR/calls is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›CVRX

CVRX

CVRx, Inc.

Next earnings Aug 3, 2026 (after close) · consensus $-0.53 EPS, $15.9M rev

Last earnings -12.3% on 2026-05-11

Sell
$5.86
▲ +11.62%
$5.86▲ +0.69%
over 1Y
L $4.74EODHDH $10.81
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+11.6%
1W+11.6%
1M+1.4%
3M-34.2%
YTD-17.5%
1Y+0.7%
OverviewFinancialsValuationQualityTimelineFilings
Rating
Sell
Quality
C-
Valuation
Fair value
Filings
Watch
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 13 analysts
Buy

Revenue grew 10.4% YoY; but unprofitable (net margin -94.1%).

Revenue (FY2025) $56.7M · FY2025

CVRx, Inc. shows $56.7M in FY2025 revenue (+10.4% YoY), a -94.1% net margin, and -135.6% ROE.

Financials · annual, by fiscal year

Line itemFY21FY22FY23FY24FY25
Revenue$13.0M$22.5M$39.3M$51.3M$56.7M
Gross profit$9.40M$17.5M$33.0M$43.0M$48.3M
Operating income-$26.0M-$42.5M-$43.1M-$59.5M-$51.3M
Net income-$43.1M-$41.4M-$41.2M-$60.0M-$53.3M
Diluted EPS-$4.16-$2.02-$1.99-$2.65-$2.04
Net margin-330.5%-184.4%-104.8%-116.9%-94.1%

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$128M
EV / EBITDA—
EV / Sales2.3
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-34.6%
FCF yield-26.4%

Quality & risk

ROIC (est.)-45.6%
Free cash flow-$40.8M
Total debt$49.5M
Net cash$26.2M
Altman Z-Score-6.54 distress
Piotroski F-Score3/9

Capital returns

Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+1.1%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timeline

SEC · 8-Ks + reports
Some governance/structural items recently, but no outright red flags.
  1. 8-K Officer / director change2026-06-09
  2. 8-K Shareholder vote2026-06-03
  3. 10-Q Quarterly report2026-05-12
  4. 8-K Earnings results2026-05-11
  5. DEF 14A Proxy statement2026-04-20
  6. 8-K Earnings results2026-04-13
  7. 8-K Officer / director change2026-03-03
  8. 10-K Annual report2026-02-13
  9. 8-K Earnings results2026-02-12

Recent filings

all on EDGAR ↗
8-KPeriod ending 2026-06-072026-06-09open ↗4Period ending 2026-06-012026-06-03open ↗4Period ending 2026-06-012026-06-03open ↗4Period ending 2026-06-012026-06-03open ↗4Period ending 2026-06-012026-06-03open ↗4Period ending 2026-06-012026-06-03open ↗4Period ending 2026-06-012026-06-03open ↗4Period ending 2026-06-012026-06-03open ↗3Period ending 2026-06-012026-06-03open ↗8-KPeriod ending 2026-06-012026-06-03open ↗SDFiling2026-05-28open ↗10-QPeriod ending 2026-03-312026-05-12open ↗

Quality score

C-
ValueGrowthProfitHealthMom.
ValueB
GrowthB
ProfitabilityF
Financial healthC
Momentum—
  • ✓Revenue growing year-over-year
  • ✗Profitable (positive net income)
  • ✗Net margin above 10%
  • ✗Return on equity above 15%
  • ✓Liabilities below 2× equity
Revenue
$56.7M
+10.4% YoY
Net margin
-94.1%
ROE
-135.6%
P/E
—

SEC fundamentals · FY 2025

'21'22'23'24'25

■ revenue · ■ net income, by fiscal year

Revenue$56.7M+10.4%
Net income-$53.3M+11.1%
Gross profit$48.3M+12.5%
Operating income-$51.3M+13.8%
Diluted EPS-$2.04+23.0%
Cash & equivalents$75.7M-28.5%
Total assets$105M-21.5%
Total liabilities$65.5M+5.0%
Stockholders' equity$39.3M-44.7%
Gross: 85.3%Op.: -90.5%L/E: 1.66x

Frequently asked

Is CVRx, Inc. (CVRX) a buy?
CVRX currently carries a Sell rating with 3/5 conviction, derived from its latest SEC filings. Revenue grew 10.4% YoY; but unprofitable (net margin -94.1%).
What is CVRx, Inc.'s quality score?
CVRX scores 52.09803921568628/100 (grade C-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0001235912, latest 10-Q filed 2026-05-12) · EODHD · as of 6/26/2026, 7:26:16 PM.

Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC
2026-06-01
Nielsen Kirk G.
Director
Award8.72K
2026-06-01
Jain Mudit K.
Director
Award8.72K
2026-06-01
SLATTERY JOSEPH P
Director
Award8.72K
2026-06-01
Hill, Mitch C.
Director
Award8.72K
2026-06-01
Ballinger Kevin J.
Director
Award8.72K
2026-06-01
SHADAN MARTHA
Director
Award8.72K
2026-06-01
DALE MICHAEL D
Director
Award29.0K
2026-03-02
Adamson Philip B.
Chief Medical Officer
Sell1.26K @ $7.90$9.97K
2026-02-27
Adamson Philip B.
Chief Medical Officer
Award41.0K

Earnings history

beat/miss · move
2026-05-11Beat +2.8% est▲ +1.32%8-K ↗
2026-04-13Beat +2.8% est▲ +9.15%8-K ↗
2026-02-12Miss -2.8% est▼ -6.41%8-K ↗
2026-01-12Miss -2.8% est▼ -9.86%8-K ↗
2025-11-05Beat +4.2% est▼ -2.00%8-K ↗
2025-08-04Miss -7.5% est▼ -0.13%8-K ↗

Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.

Recent news

market news →
CVRx Stock Up on Humana's Medicare Coverage for Barostim TherapyBullish
finance.yahoo.com· 2026-05-18
CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim TherapyBullish
finance.yahoo.com· 2026-05-14
CVRx Q1 Earnings Call HighlightsBullish
finance.yahoo.com· 2026-05-11
CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded PopulationBullish
globenewswire.com· 2026-05-04
CVRx sees Q1 revenue in the range of $14.7M to $14.8MBullish
seekingalpha.com· 2026-04-13
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRXBullish
globenewswire.com· 2026-03-03

Vs tracked universe

compare →

1044 tracked peers · median

EDGAR Score52 vs 67
Revenue growth10.4% vs 7.1%
Net margin-94.1% vs 10.5%
Return on equity-135.6% vs 12.3%
P/E— vs 25.5

News sentiment

EODHD · 4d
Bullish
+0.18
vs typical · 4 articles
↑ improving

Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.